Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Last updated: July 22, 2024
Sponsor: Uromedica
Overall Status: Active - Recruiting

Phase

N/A

Condition

Enuresis

Urinary Incontinence

Treatment

Adjustable Continence Therapy for Women (ACT)

Clinical Study ID

NCT04248283
UM08
  • Ages > 22
  • Female

Study Summary

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Female at least 22 years old

  2. Diagnosed with stress urinary incontinence with primary Intrinsic SphincterDeficiency

  3. Provocative pad weight of greater than 11.0 grams

  4. Candidate for surgical intervention

  5. Negative urinalysis

  6. Normal cystourethroscopy

  7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note:patients may have failed prior anti-incontinence procedures for SUI (e.g.,suspension, sling, or urethral bulking agent)

  8. Willing and able to sign informed consent and comply with trial follow-uprequirements

Exclusion

Exclusion Criteria:

  1. Pregnant or lactating

  2. Life expectancy of less than 5 years

  3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucoseover 130 mg/dL

  4. Has auto-immune disease

  5. Undergoing radiation therapy

  6. Active urinary tract infection

  7. Detrusor instability refractory to medication

  8. Reduced bladder compliance as defined by a cystometrogram

  9. Significant residual volume (greater than 100 ml) after voiding in which detrusorcontraction is weak, when the bladder volume is greater than or equal to 250 ml

  10. Has, had, or is suspected of having bladder cancer

  11. History of bladder stones

  12. Urethral stricture evidenced during cystourethroscopy

  13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia

  14. Has a diathesis, hemophilia, or a bleeding disorder

  15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3or higher

  16. Had prior pelvic radiotherapy

  17. Had a prior artificial urinary sphincter implanted

  18. Has a neurogenic condition known to affect bladder/sphincter function

Study Design

Total Participants: 167
Treatment Group(s): 1
Primary Treatment: Adjustable Continence Therapy for Women (ACT)
Phase:
Study Start date:
January 26, 2021
Estimated Completion Date:
December 30, 2025

Connect with a study center

  • University of Colorado

    Denver, Colorado 80045
    United States

    Active - Recruiting

  • Ochsner Health

    New Orleans, Louisiana 70121
    United States

    Site Not Available

  • Kansas City Urology Care

    Overland, Missouri 66211
    United States

    Site Not Available

  • CHI Health Research Center

    Omaha, Nebraska 68124
    United States

    Active - Recruiting

  • Virtua Health, Inc.

    Moorestown, New Jersey 08057
    United States

    Site Not Available

  • The Institute for Female Pelvic Medicine and Reconstructive Surgery

    Allentown, Pennsylvania 18103
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Site Not Available

  • University of Washington

    Seattle, Washington 98195
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.